RT Journal
A1 Hiatt WR, Goldfine AB, Kaul S
T1 CArdiovascular risk assessment in the development of new drugs for obesity
JF JAMA
JO JAMA
YR 2012
FD September 19
VO 308
IS 11
SP 1099
OP 1100
DO 10.1001/jama.2012.9931
UL http://dx.doi.org/10.1001/jama.2012.9931
AB 
The US Food and Drug Administration (FDA), Center for Drug Evaluation and Research, convened a meeting of the Division of Metabolism and Endocrinology Products on March 28-29, 2012, to consider cardiovascular safety requirements for approval of new drugs to treat obesity. The broader context at that time involved 4 recent individual drug product reviews, resulting in no new antiobesity drugs approved and 1 drug (sibutramine) withdrawn from the market.1 For pharmacologic weight loss to be more than cosmetic, it is essential to demonstrate measurable health benefits. Because obesity is associated with excess cardiovascular risk and weight loss treatments could potentially mitigate that risk, it is important to assess the effect of these drugs on cardiovascular morbidity and mortality.